Floating tablets of carbamazepine were developed using melt granulation technique. Bees wax was used as a hydrophobic meltable material. Hydroxypropylmethylcellulose, sodium bicarbonate and ethyl cellulose were used as matrixing agent, gas-generating agent and fl oating enhancer, respectively. The tablets were evaluated for in vitro buoyancy and dissolution studies. A simplex lattice design was applied to investigate the combined effect of 3 formulation variables i.e. amount of hydroxypropyl methylcellulose (X 1 ), ethyl cellulose (X 2 ) and sodium bicarbonate (X 3 ). The fl oating lag time (F lag ), time required for 50% (t 50 ) and 80% drug dissolution (t 80 ) were taken as responses. Results of multiple regression analysis indicated that, low level of X 1 and X 2 , and high level of X 3 should be used to manufacture the tablet formulation with desired in vitro fl oating time and dissolution. Formulations developed using simplex lattice design were fi tted to various kinetic models for drug release. Formulation S3 was selected as a promising formulation and was found stable at 40 o and 75% relative humidity for 3 months. Present study demonstrates the use of simplex lattice design in the development of fl oating tablets with minimum experimentation.
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The high cost involved in the development of a new drug molecule has diverted the pharmaceutical companies to investigate various strategies in the development of new drug delivery systems 1 . Drug release from the delivery devices can be sustained up to 24 h for many drugs using current release technologies. However, the real issue in the development of oral controlled release dosage forms is to prolong the residence time of the dosage form in the stomach or upper gastrointestinal (GI) tract until the drug is completely released 2 .
Several approaches are currently used to retain the dosage form in the stomach. These include bioadhesive systems 3 , swelling and expanding systems 4, 5 , floating systems 6, 7 and other delayed gastric emptying devices 8, 9 . The principle of ß oating preparation offers a simple and practical approach to achieve increased gastric residence time for the dosage form and sustained drug release.
Carbamazepine (CBZ) is used for anticonvulsant and antineuralgic effects. The popularity of this drug is related to several beneficial properties, including, proven efficacy in controlling different types of seizures. It is poorly soluble in water with erratic oral absorption and bioavailability less than 70%. Moreover CBZ has a narrow therapeutic range and shows bioavailability differences 10 . In efforts to reduce the frequency of dosing required for chronic CBZ therapy and to decrease variability in plasma concentration, various extended release formulations have been developed by many researchers [11] [12] [13] . Preparing the drug in a floating dosage form can control the extent of bioavailability for such poorly water-soluble drug. The objective of the present investigation is to develop floating tablets containing carbamazepine using simplex lattice design as an optimization technique.
MATERIALS AND METHODS
Carbamazepine USP was a gift from Hindustan Chemicals Ltd., Chennai, India. Bees wax was purchased from Ases Chemical Works, Jodhpur, India. Hydroxypropyl methylcellulose K4 M (HPMC K4 M), ethyl cellulose (EC) and sodium bicarbonate were purchased from Laser Chemicals, Ahmedabad, India. Magnesium stearate and talc were purchased from Apex Chemicals, Ahmedabad, India. All other ingredients used were of analytical grade and used as received.
Preparation of carbamazepine fl oating tablets:
Bees wax was melted in a large petridish and the required quantity of CBZ was added to the molten mass. Previously prepared geometric mixture of HPMC K4 M and/or EC and sodium bicarbonate was added to the molten CBZ-bees wax mixture and stirred well to mix. The mass was removed from the hot plate and subjected to scrapping until it attained room temperature. The coherent mass was passed through 60 mesh and the resulting granules were resifted using100 mesh to separate the Þ nes. The granules (50 g) of 60/100 mesh were collected and mixed with talc (2%) and magnesium stearate (1%). This lubricated blend was compressed into tablets using 12 mm ß at face round tooling on a Rimek-I rotary tablet machine (Karnavati Eng. Pvt. Ltd, Ahmedabad). Compression force was adjusted to obtain tablets with hardness in range of 5-6 kg/cm 2 . Tablets were weighing 515±4 mg round ß at face with average diameter of 12±0.1 mm and thickness of 4.6±0.2 mm. Formulations of the preliminary trial batches (P1 to P7) and the simplex lattice design batches (S1 to S7) are shown in Tables  1 and 2 , respectively.
In vitro buoyancy studies:
In vitro buoyancy was determined by floating lag time as per the method described by Rosa et al 14 . The tablets were placed in a 100 ml glass beaker containing simulated gastric ß uid (SGF), pH 1.2 as per USP. The time required for the tablet to rise to the surface and ß oat was determined as ß oating lag time.
In vitro dissolution studies:
The in vitro dissolution study of CBZ tablets was performed using USP apparatus (model TDT-06T, Electrolab, India) fitted with paddles (75 rpm) at 37±0.5 o using simulated gastric fluid (pH 1.2; 900 ml) as a dissolution media. At the predetermined time intervals, 10 ml samples were withdrawn, Þ ltered through 0.45 µ membrane Þ lter, diluted, and assayed at 285 nm using a Shimadzu UV/Vis double beam spectrophotometer (Kyoto, Japan). Cumulative percentage drug release was calculated using an equation obtained from the calibration curve. The drug release proÞ le is shown in Þ g. 1. The time required for 50% and 80% drug release was calculated.
Simplex lattice design:
A simplex lattice design 15 was adopted to optimize the formulation variables. In this design, three factors were evaluated by changing their concentrations simultaneously and keeping their total concentration constant. The simplex lattice design for three- All batches contained 40% w/w carbamazepine, 2% w/w talc and 1% w/w magnesium stearate. Average weight of each tablet is 515 mg. fig. 2 ) in two-dimensional space. Seven batches (S1 to S7) were prepared, one at each vertex (A, B, C), one at half way between vertices (AB, BC, AC) and one at the center point (ABC). Each vertex represents, a formulation containing the maximum amount of one component, with the other two components at a minimum level. The half way between the two vertices represents, a formulation containing the average of the minimum and maximum amount of the two ingredients represented by two vertices. The center point represents, a formulation containing one third of each ingredient. The amounts of matrixing agent, HPMC K4 M (X 1 ), gas-generating agent, sodium bicarbonate (X 2 ) and ß oating enhancer, EC (X 3 ), were selected as independent variables. The ß oating lag time (F lag ), time required for 50% (t 50 ) and 80% drug dissolution (t 80 ) were taken as responses.
Kinetic modeling of drug release:
The dissolution proÞ le of all the batches was Þ tted to various models like zero-order, Þ rst-order 16 [22] [23] [24] to ascertain the kinetic modeling of drug release. The method of Bamba et al, was adopted for deciding the most appropriate model 25 .
RESULTS AND DISCUSSION
Bees wax was selected as a hydrophobic meltable material to impart sufÞ cient integrity to the tablets. HPMC K4 M was selected as a matrixing agent considering its widespread applicability and excellent gelling activity in sustained release formulations. Sodium bicarbonate generates CO 2 gas in the presence of hydrochloric acid present in dissolution medium. The gas generated is trapped and protected within the gel formed by hydration of HPMC K4 M, thus decreasing the density of the tablet. As the density of the tablet falls below 1 (density of water), the tablet becomes buoyant. EC was used as ß oating enhancer. It also works as a dissolution retardant being insoluble in gastric pH. Five batches (P1 to P5) were prepared using same amounts of sodium bicarbonate and bees wax while different amounts of HPMC K4 M and EC. The amount of HPMC K4 M was decreased while EC was increased from batch P1 to P5. From the evaluation results (Table 1) , it was observed that as the amount of EC was increased from 0% to 25%, F lag was decreased and this effect was signiÞ cant on reducing F lag up to 10% of EC. Hence it was decided to optimize the amount of EC in between 0% and 10%. As the amount of HPMC K4 M was increased from 20% to 45%, the F lag was increased indicating that high amount of HPMC K4 M is undesirable to achieve low F lag . Below 25%, HPMC K4 M might not give sufÞ cient strength to the matrix to prolong drug release up to 12 h. Hence, it was decided to optimize HPMC K4 M in between 25% and 35%. Formulations P1 to P5 were subjected to in vitro dissolution study. All the tablets ruptured within 3 h with more than 80% drug release. This might be due to poor strength of tablets or due to insufficient binding provided by bees wax that failed to keep the matrix intact. Formulations P6 and P7 were prepared using 15% and 20% of bees wax, respectively. These were found to remain intact for more than 12 h under stirring at 75 rpm during dissolution studies. Formulation P7 exhibited floating lag time of 325 s. This might be due to poor penetration of SGF in a tablet core due to high amount of bees wax. Hence it was decided to keep the bees wax at 15%. It is well known that higher percentage of sodium bicarbonate decreases the F lag . So it was decided to optimize sodium bicarbonate between 10% and 20% to keep the F lag below 3 min. In order to optimize the formulation for acceptance criteria of F lag , less than 3 min; t 50 , in between 300 and 420 min; and t 80 , in between 540 and 600 min; a simplex lattice design was employed in the present investigation.
The amounts of matrixing agent (HPMC K4 M, X 1 ), gas-generating agent (sodium bicarbonate, X 2 ) and floating enhancer (EC, X 3 ) were selected as independent variables in a simplex lattice design. The floating lag time (F lag ) and times required for 50% (t 50 ) and 80% drug dissolution (t 80 ) were taken as responses. A statistical model incorporating seven interactive terms was used to evaluate the responses.
, where Y is the dependent variable, b 0 is the arithmetic mean response of seven runs and b i is the estimated coefÞ cient for factor X i . The main effects (X 1, X 2 and X 3 ) represent the average result of changing 1 factor at a time from its low to high value. The interaction terms (X 1 X 2, X 2 X 3, X 1 X 3 and X 1 X 2 X 3 ) show how the response changes when two or more factors are simultaneously changed. The statistical analysis of simplex lattice design batches was performed by multiple linear regression analysis using Microsoft Excel. The values ( The high values of correlation coefÞ cients for F lag , t 50 and t 80 indicate a good fit i.e., good agreement between the dependent and independent variables. The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries (i.e., positive or negative). The equation for F lag suggests that the factor X 1 has more significant effect on floating lag time followed by factor X 2 and X 3 . Therefore, high level of factor X 1 should not be selected for lower floating lag time. From the equation 3 and equation 4, it can be concluded that, factor X 1 has more important role in prolonging both, t 50 and t 80 . The magnitude of coefficients indicates that factor X 2 has more favorable effect on both the dependent variables than factor X 3 . The high value of X 1 X 2 coefÞ cient also suggests that the interaction between X 1 and X 2 has a signiÞ cant effect on t 50 and t 80 . From the results of multiple linear regression analysis, it can be concluded that the drug release pattern can be changed by appropriate selection of the X 1 , X 2 and X 3 levels.
The promising formulation was selected on the basis of the acceptance criteria for F lag , t 50 and t 80 as mentioned earlier. Formulations S2, S3, S5 and S7 passed the criteria for F lag . Formulations S2, S3, S5 and S6 passed the criteria for t 50 . The criterion for t 80 was fulfilled only by formulation S3. Hence formulation S3 was selected as promising formulation from the simplex lattice design batches.
All the simplex lattice design batches showed good in vitro buoyancy with maximum ß oating lag time of 255 s. All the tablet formulations remained buoyant for more than 12 h in SGF, pH 1.2. In vitro buoyancy study was also conducted at an elevated pH condition (pH 4.5). The ß oating tendency of all the formulations remained unaltered at higher pH.
The dissolution data of batches S1 to S7 was Þ tted to zero-order, first-order, Higuchi, Hixon-Crowell, Korsmeyer and Peppas, and Weibull models. The factorial batches were subjected to short-term stability studies at 40 o and 75% RH for three mo. Samples withdrawn after three mo showed no signiÞ cant change in appearance of the tablets, ß oating lag time and in vitro drug release.
Based on the results it was concluded that the addition of matrixing polymer, HPMC K4 M, and gas generating agent, sodium bicarbonate was essential to achieve in vitro buoyancy. A systematic study using a simplex lattice design revealed that the amount of HPMC K4 M, sodium bicarbonate and EC had a signiÞ cant effect on F lag , t 50 and t 80 . Thus, by selecting a proper optimization technique, proper balance of formulation variables can be achieved rapidly with minimum efforts to produce required in vitro buoyancy and drug dissolution proÞ le.
